IQVIA (NYSE:IQV) Given New $265.00 Price Target at Evercore ISI

IQVIA (NYSE:IQV) had its price objective trimmed by Evercore ISI from $270.00 to $265.00 in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Several other research firms also recently weighed in on IQV. Argus raised shares of IQVIA to a strong-buy rating in a research note on Wednesday, July 31st. UBS Group upped their price target on IQVIA from $295.00 to $300.00 and gave the stock a buy rating in a research note on Tuesday, July 23rd. Truist Financial boosted their price objective on IQVIA from $292.00 to $300.00 and gave the company a buy rating in a report on Tuesday, July 23rd. StockNews.com cut IQVIA from a buy rating to a hold rating in a report on Friday, September 27th. Finally, Jefferies Financial Group lowered shares of IQVIA from a buy rating to a hold rating and decreased their price target for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has an average rating of Moderate Buy and a consensus target price of $269.36.

IQVIA Stock Down 0.4 %

Shares of NYSE:IQV opened at $229.24 on Tuesday. IQVIA has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The business’s 50-day moving average is $239.41 and its 200-day moving average is $231.99. The company has a market capitalization of $41.79 billion, a price-to-earnings ratio of 29.77, a P/E/G ratio of 2.18 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.22 EPS. Equities research analysts predict that IQVIA will post 10.25 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Jennison Associates LLC boosted its holdings in shares of IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after buying an additional 9,578 shares during the last quarter. Nomura Holdings Inc. purchased a new position in IQVIA in the fourth quarter valued at about $857,000. PGGM Investments grew its position in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares during the period. Fiduciary Alliance LLC bought a new stake in shares of IQVIA in the 1st quarter worth approximately $1,864,000. Finally, SG Americas Securities LLC raised its holdings in shares of IQVIA by 80.1% in the 1st quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock worth $11,579,000 after purchasing an additional 20,369 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.